PKPD Modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
Open Access
- 20 November 2013
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 2 (11), 1-9
- https://doi.org/10.1038/psp.2013.61
Abstract
The predictive value of longitudinal biomarker data (vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR)‐2, sVEGFR‐3, and soluble stem cell factor receptor (sKIT)) for tumor response and survival was assessed based on data from 303 patients with imatinib‐resistant gastrointestinal stromal tumors (GIST) receiving sunitinib and/or placebo treatment. The longitudinal tumor size data were well characterized by a tumor growth inhibition model, which included, as significant descriptors of tumor size change, the model‐predicted relative changes from baseline over time for sKIT (most significant) and sVEGFR‐3, in addition to sunitinib exposure. Survival time was best described by a parametric time‐to‐event model with baseline tumor size and relative change in sVEGFR‐3 over time as predictive factors. Based on the proposed modeling framework to link longitudinal biomarker data with overall survival using pharmacokinetic–pharmacodynamic models, sVEGFR‐3 demonstrated the greatest predictive potential for overall survival following sunitinib treatment in GIST. CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e84; doi:10.1038/psp.2013.61; advance online publication 20 November 2013Keywords
This publication has 35 references indexed in Scilit:
- PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib‐Treated Patients With GISTCPT: Pharmacometrics & Systems Pharmacology, 2013
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib FailureClinical Cancer Research, 2009
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failureEuropean Journal Of Cancer, 2009
- Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markersBMC Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Predicting benefit from anti-angiogenic agents in malignancyNature Reviews Cancer, 2006
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Comparison of four basic models of indirect pharmacodynamic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1993